Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

286
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
286
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.3K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
Angina IV: Management01:26

Angina IV: Management

205
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
205
Lipids: Dietary Sources and Requirements01:18

Lipids: Dietary Sources and Requirements

1.8K
Lipids are an essential component of a balanced human diet. Triglycerides, which make up the majority of dietary lipids, are found in both saturated fats—commonly present in meat, dairy products, and certain tropical plants like coconut, and hydrogenated oils such as margarine and baking shortenings (trans fats)—and unsaturated fats, which are abundant in seeds, nuts, olive oil, and most vegetable oils. The main sources of cholesterol include egg yolks, various meats and organ...
1.8K
Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

4.6K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
4.6K
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

530
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
530

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Generating Practice-Based Evidence in the Use of Guideline-Recommended Combination Therapy for Secondary Prevention of Acute Myocardial Infarction.

Pharmacy (Basel, Switzerland)·2022
Same author

Association of Low-Density Lipoprotein Cholesterol Levels with More than 20-Year Risk of Cardiovascular and All-Cause Mortality in the General Population.

Journal of the American Heart Association·2022
Same author

Producing personalized statin treatment plans to optimize clinical outcomes using big data and machine learning.

Journal of biomedical informatics·2022
Same author

Trans Fatty Acid Biomarkers and Incident Type 2 Diabetes: Pooled Analysis of 12 Prospective Cohort Studies in the Fatty Acids and Outcomes Research Consortium (FORCE).

Diabetes care·2022
Same author

Effectiveness of a Novel ω-3 Krill Oil Agent in Patients With Severe Hypertriglyceridemia: A Randomized Clinical Trial.

JAMA network open·2022
Same author

Self-controlled assessment of thromboembolic event (TEE) risk following intravenous immune globulin (IGIV) in the U.S. (2006-2012).

Journal of thrombosis and thrombolysis·2021
Same journal

Multimodality imaging of vulnerable plaque: Are we there yet? A multifaceted perspective.

Progress in cardiovascular diseases·2026
Same journal

Beyond LDL-C: Triangulating residual risk via lipoprotein(a), remnant cholesterol, and vascular inflammation.

Progress in cardiovascular diseases·2026
Same journal

COVID-19 and coronary atherosclerosis: Unmasking and accelerating?

Progress in cardiovascular diseases·2026
Same journal

Mavacamten and left ventricular dysfunction in hypertrophic cardiomyopathy with left bundle branch block.

Progress in cardiovascular diseases·2026
Same journal

Lessons from ATTR-CM clinical trials: Progress, persistent disparities, and emerging treatment dilemmas.

Progress in cardiovascular diseases·2026
Same journal

Circulating microRNA signatures associated with atrial remodeling in endurance athletes with PAFIYAMA syndrome: A case-control study.

Progress in cardiovascular diseases·2026
See all related articles

Related Experiment Video

Updated: Jan 4, 2026

Assessing Whole-Body Lipid-Handling Capacity in Mice
07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

4.6K

Lipid management beyond the guidelines.

Jennifer G Robinson1

  • 1Departments of Epidemiology and Internal Medicine, Division of Cardiology, University of Iowa.

Progress in Cardiovascular Diseases
|November 1, 2019
PubMed
Summary
This summary is machine-generated.

Updated cholesterol guidelines emphasize statin therapy for primary prevention, supported by new evidence on nonstatin therapies like PCSK9 inhibitors. Early intervention with statins and risk factor management in young adults is crucial for reducing atherosclerotic cardiovascular disease (ASCVD) events.

Keywords:
Calcium scoringCardiovascular preventionCost-effectivenessEzetimibePCSK9 inhibitorsStatins

More Related Videos

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.0K
Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

2.6K

Related Experiment Videos

Last Updated: Jan 4, 2026

Assessing Whole-Body Lipid-Handling Capacity in Mice
07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

4.6K
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.0K
Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

2.6K

Area of Science:

  • Cardiovascular Medicine
  • Preventive Cardiology
  • Pharmacotherapy

Background:

  • The 2018 AHA/ACC cholesterol guideline expanded on 2013 recommendations for statin therapy.
  • New data necessitate further refinement of nonstatin therapy use and risk stratification for primary prevention.
  • Evolving understanding of lipid management and cardiovascular risk factors informs current clinical practice.

Purpose of the Study:

  • To review recent evidence impacting clinical practice beyond the 2018 AHA/ACC cholesterol guideline.
  • To highlight the value of nonstatin therapies and advanced risk assessment tools.
  • To emphasize the importance of early intervention for long-term cardiovascular health.

Main Methods:

  • Analysis of meta-analyses and clinical trial data on lipid-lowering therapies.
  • Review of data on Proprotein convertase subtilisin kexin type-9 (PCSK9) monoclonal antibodies and icosapent ethyl.
  • Evaluation of coronary artery calcium (CAC) scoring in younger populations and its relation to statin therapy.
  • Examination of epidemiologic studies on early-life cholesterol levels and future ASCVD risk.

Main Results:

  • PCSK9 inhibitors offer good value, particularly for high-risk patients needing further low-density lipoprotein cholesterol (LDL-C) reduction.
  • Higher baseline LDL-C (≥100 mg/dL) correlates with greater risk reduction for cardiovascular events and mortality.
  • Icosapent ethyl demonstrates efficacy in reducing cardiovascular events in high-risk patients with moderate hypertriglyceridemia.
  • Statin initiation for individuals with ≥7.5% 10-year ASCVD risk is the most effective strategy for event reduction.
  • CAC scoring (CAC > 0) identifies individuals likely to benefit from statins; statins may prevent CAC progression.
  • Elevated LDL-C and non-high-density lipoprotein cholesterol in young adulthood predict increased later-life ASCVD risk.

Conclusions:

  • Recent evidence supports expanded use of nonstatin therapies and refined risk stratification for ASCVD prevention.
  • Early statin initiation, especially in individuals with elevated CAC scores or significant ASCVD risk, is paramount.
  • Addressing lipid levels in young adulthood is critical for mitigating long-term cardiovascular disease risk, warranting further research into early intervention strategies.